Oncolytic viruses are known to stimulate the antitumor immune response by specifically replicating in tumor cells. This is believed to be an important aspect of the durable responses observed in some patients and the field is rapidly moving toward immunotherapy. As a further means to engage the immune system, we engineered a virus, vesicular stomatitis virus (VSV), to encode the proinflammatory cytokine interferon-γ. We used the 4T1 mammary adenocarcinoma as well as other murine tumor models to characterize immune responses in tumor-bearing animals generated by treatment with our viruses. The interferon-γ-encoding virus demonstrated greater activation of dendritic cells and drove a more profound secretion of proinflammatory cytokines compared to the parental virus. From a therapeutic point of view, the interferon-γ virus slowed tumor growth, minimized lung tumors, and prolonged survival in several murine tumor models. The improved efficacy was lost in immunocompromized animals; hence the mechanism appears to be T-cell-mediated. Taken together, these results demonstrate the ability of oncolytic viruses to act as immune stimulators to drive antitumor immunity as well as their potential for targeted gene therapy.
INTRODUCTION
The capability to evade the immune system is essential for tumor establishment and has been identified as a hallmark of cancer. 1 Conversely, an effective antitumor immune response against tumor-associated antigens is believed to prevent relapse of the disease. 2 Various proinflammatory cytokines stimulate immunity and their exogenous administration has been used for the treatment of many cancers. 3 Among these, interferon-γ (IFNγ), has a myriad of roles in both arms of immunity. 4 It is mainly produced by T cells, natural killer (NK) cells, and macrophages and has effects on all nucleated cells of the body. 5 It is a powerful immune modulator that has antiproliferative, proapoptotic, and antiangiogenic functions. 5, 6 It also induces adaptive immunity through increased antigen presentation and T-cell activation. 7 The pivotal role of IFNγ in tumor immunosurveillance is exemplified by the observation that mice deficient for the IFNγ receptor develop tumors more rapidly and at a higher frequency. 8 Many observations show that the presence of IFNγ might be beneficial in the treatment of various cancers. For examples, in human breast cancer samples, the expression of IFNγ and its receptor were reported to be increased in benign lesions compared to malignant lesions. 9 Because of these observations, along with its many protective functions against cancer and its immune-stimulating properties, IFNγ has long been considered a promising candidate for the treatment of various malignancies. 5 It was demonstrated using the 4T1 murine breast cancer model that intratumoral (IT) administration of IFNγ reduces metastases to the lungs and liver. 10 In the clinic, it has been shown that that local injection of IFNγ in skin lesions of breast cancer patients resulted in partial regression. 11 Also, recombinant human IFNγ-1b has successfully been used to delay progression of microbial infections in chronic granulomatous disease, 12 but its use in human cancer treatment has given mixed results. [13] [14] [15] [16] One of the reasons for the limited efficacy was attributed to the very short half-life of IFNγ in serum and therefore, local expression is a more promising approach. 17 One successful strategy to deliver genes to the tumor site is to use viruses. Indeed, the direct IT injection of virus expressing IFNγ demonstrated efficacy in two different xenograft models. 18 Tumor-specific oncolytic viruses (OV) encoding transgenes have also been shown to be an efficient tool to drive sustained local transgene expression. 19, 20 OVs like the vesicular stomatitis virus (VSV) were selected to specifically destroy tumor cells while leaving normal tissues unaffected. 21 While normal cells are protected by type I IFNs, cancer cells frequently acquire defects in this pathway. Thus, normal, but not tumor cells, will be protected against VSV. 22 To further attenuate VSV, a deletion in its M protein (VSVΔ51), which prevents the blockade of the IFN response, has been developed for clinical use. 23 OVs destroy tumors by several mechanisms. Of these, the direct oncolysis of cancer cells is an important aspect. 21 Nevertheless, the potential of VSV as an immunotherapy agent is under-studied. 19 By destroying cancer cells, viruses liberate tumor-associated antigens in the presence of pathogen-associated molecular patterns, which stimulates antitumor immunity. 24 This can result in long-lasting immune responses that target both primary tumors and metastases. 25 In this study, we engineered VSVΔ51 to express murine IFNγ. In murine tumor models, we demonstrate in vivo expression of functional IFNγ within the tumor microenvironment. Compared to the parental virus, VSVΔ51-IFNγ elicited secretion of proinflammatory factors in the blood, enhanced activation of dendritic cells (DCs), and generated a greater tumor-specific immune response.
ReSUlTS
IFNγ expression does not affect the ability of VSV to replicate and kill tumor cells We engineered the virus to encode the murine IFNγ gene between the G and L genes (Figure 1a ) based on the previous reports of successful transgene expression in this location without impairing virus replication. 26 We assessed its replication kinetics compared to the parental virus (VSVΔ51) in two different tumor cell lines. Cells were infected at a low multiplicity of infection (MOI) in vitro to generate multi-step growth curves. In both the 4T1 mammary and the CT26 colon carcinoma cell lines, we obtained nearly overlapping growth curves when comparing the two viruses (Figure 1b,c) , demonstrating that the expression of IFNγ by VSVΔ51 does not affect its replication in these cell lines. To investigate the cytolytic capabilities of the viruses, we infected the same cell lines at various MOIs and quantified their metabolic activity. As expected, we observed a dose-dependent killing of the cells (Figure 1d ). The results obtained showed no difference for the two viruses; thus, the expression of IFNγ does not influence viral cytotoxicity. Notably, our data indicate a greater sensitivity of the CT26 cells compared with the 4T1 cells as approximately 10-fold more virus (Figure 1b ,c) and 25% more killing (Figure 1d ) are observed for the CT26 cells.
To confirm transgene expression, 4T1 and CT26 cells were infected with virus and the expression of IFNγ was assessed by flow cytometry. IFNγ was detected only in cells infected with VSVΔ51-IFNγ (Figure 2a) . To quantify the amount of IFNγ produced, supernatants from infected cells were collected at various time points after infection and the concentration of IFNγ was assessed by enzyme-linked immunosorbent assay (ELISA). We observed secretion of significant amounts of IFNγ in both cell lines infected with VSVΔ51-IFNγ while none was detected from cells infected with the parental virus (Figure 2b ). The IFNγ produced by 4T1 cells plateaued at 14,000 pg/ml at 24 hours, while CT26 cells reached 35,000 pg/ml at 48 hours postinfection. These findings are in agreement with the increased replication and killing by VSV in CT26 cells as compared to 4T1 cells (Figure 1b-d) .
IFNγ encoded by VSV is functional Upon IFNγ binding to its receptor, the signal transducer and activator of transcription (STAT1) is phosphorylated and translocates to the nucleus to induce transcription of target genes. 4 Thus, to assess the functionality of IFNγ, we evaluated the phosphorylation of STAT1 as well as its nuclear translocation mediated by virus-cleared supernatants of infected tumor cells. The concentration of IFNγ was determined by ELISA and diluted to 100 pg/ml, a concentration that is sufficient to mediate STAT1 phosphorylation (pSTAT1) in 4T1 and CT26 cells. To assess the subcellular localization of STAT1 upon stimulation, we performed confocal microscopy on cells incubated for 60 minutes with the same conditioned media. While only a small number of cells incubated with the VSVΔ51-conditioned supernatant demonstrated a nuclear localization of STAT1, all of the cells from the IFNγ virus-conditioned media displayed nuclear localization of STAT1 (Figure 2c) . By western blot, we detected increased levels of pSTAT1 for both conditioned supernatants compared to control supernatant (Figure 2d ). However, pSTAT1 was detected earlier for the VSVΔ51-IFNγ supernatant (15 versus 30 minutes) and the bands showed a greater signal for all time points tested. In order to validate that the signal obtained for pSTAT1 was the result of direct IFNγ stimulation, we preincubated the conditioned supernatants with an IFNγ-blocking antibody. After a 20-minute stimulation, only the cells incubated with the VSVΔ51-IFNγ-conditioned media showed a band corresponding to pSTAT1 (Figure 2e) , consistent with the results obtained in Figure 2d In order to evaluate the localization of the viruses following a single IT injection in our model, we performed a complete biodistribution by plaque assay and found the virus to be restricted to the tumors at both 24 and 48 hours post-treatment (Supplementary Figure S2a) . We also performed quantitative polymerase chain reaction (qPCR) on spleen of the same animals since this technique is more sensitive and the spleen filters the blood and offers a good readout of potential leakage of virus into the bloodstream. Our results demonstrate that, at both time points, the virus was barely detectable in the spleens of the animals (Figure 3a) . To measure the expression of IFNγ and IL-6 (an IFNγ responsive gene) in the tumors, animals were treated IT (single dose) with either virus and the expression of the cytokines was measured by qPCR 24 and 48 hours post-treatment. Our data show that, although the mRNA levels of IFNγ are slightly more than 10,000-fold higher in the tumors from the animals treated with VSVΔ51-IFNγ, the expression of IL-6 remains the same for both viruses (Figure 3b ). Since we expect IL-6 and other cytokines to be mostly upregulated by immune cells, we sought to determine the systemic levels of IFNγ and various proinflammatory factors that should be upregulated in the presence of IFNγ. To do so, 4T1 tumor-bearing mice were treated IT (single dose) with phosphate-buffered saline (PBS), VSVΔ51, or VSVΔ51-IFNγ and were sacrificed 24 and 48 hours postinjection to collect blood and tumor samples. qPCR was used to quantify the amount of virus present in the tumors prior to cytokine analysis. Similar amounts of viral genomes were detected in both groups (Supplementary Figure  S2b) . If the transgene is functional in vivo, different proinflammatory factors should be increased compared to the control group. Secreted proinflammatory factors should be detected in the blood if produced in sufficient amounts, thus resulting in broader immune activation. To test this, we isolated serum from treated animals and IFNγ, interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and monocyte chemoattractant protein-1 (MCP-1) concentrations were determined using cytometric bead arrays. All the factors tested were higher in both virus-treated groups compared with PBS-treated animals ( Figure 3c,d) , consistent with an immune response to viral infection. 27 Importantly, IFNγ levels were higher in the serum of VSVΔ51-IFNγ-treated 4T1 tumor-bearing mice, reaching levels around 600 pg/ml compared to 200 pg/ml for the VSVΔ51-treated group (Figure 3c Figure S3a shows that similar amounts of VSVΔ51 and VSVΔ51-IFNγ were detected in the lungs of the 4T1 lung tumor-bearing animals 24 hours following administration of a single IV treatment. For CD3+ T cells as well as CD122+ NK cells, the expression levels of the CD69 early activation marker was assessed. 28, 29 Both viruses triggered the activation of T and NK cells, but no significant difference was observed in their activation levels when treated with the IFNγ-expressing virus at this time point (Figure 4a , right panels). For DCs (CD11c+) as well as monocytes, macrophages and granulocytes (CD11b+), the expression of the early activation marker CD86 was measured. 30 While both viruses activated DCs and granulocytes, we consistently observed an increase in CD86 mean fluorescence value on CD11c+ splenocytes from mice treated with VSVΔ51-IFNγ compared to the parental virus ( Figure 4a , left panels). Remarkably, the same phenomenon was observed 24 hours after IT injection (Figure 4b ). Similar results were also observed for CT26 lung tumor-bearing mice (Supplementary Figure S3b) . Interestingly, in the CT26 tumor model, NK-cell activation was still detectable after 48 hours, but went back to basal levels 96 hours post-treatment (Supplementary Figure S3c) .
To evaluate the antitumor immune response generated by the viruses, an IFNγ ELISPOT was performed with splenocytes isolated from immunocompetent animals following virus treatment. The spots observed following ex vivo restimulation with 4T1 target cells reflect tumor-specific activation. Our results show that, in absence of restimulation, or when the splenocytes are restimulated with a tumor cell line to which the animals were never exposed (EMT6), most animals showed no activation of splenocytes ( 
delivery in the 4T1 lung-tumor model. Given the extreme aggressiveness of this model and difficulty in observing survival advantages, alternate readouts of efficacy were utilized. We used both early and a late treatment schedules (illustrated in Figure 5a ) and looked at lung tumors. When mice were treated early posttumor seeding, analysis of the lungs revealed fewer tumors for both virus-treated groups compared with the control group (Figure 5b ,c), with VSVΔ51-IFNγ being more efficient, reducing the average amount of lung tumor nodules (61 for VSVΔ51-IFNγ compared to 185 for the untreated mice and 112 for the control virus) (Supplementary Figure S4a) . This reduction in tumor numbers was also accompanied by a modest prolongation of survival (Supplementary Figure S4b) . When mice were treated 11 days post-tumor seeding, lung tumors showed a reduction in size following treatment with both viruses when assessed by H&E staining. Representative pictures are shown in Figure 5d . When all the tumors from the H&E of the lungs were measured, we observed a significant difference in the mean tumor diameter with both viruses performing better than PBS and the IFNγ-encoding virus showing the smallest tumors (average of 329 µm for VSVΔ51-IFNγ, 412 µm for VSVΔ51, and 687 µm for control mice) ( Figure  5e ). Furthermore, when the tumors were subdivided into groups according to their size and the percentage of tumors belonging to each group was calculated, it was clear that the tumors from mice treated with the IFNγ-expressing virus were much smaller than the ones from the other groups (Figure 5f ). We investigated the efficacy of VSVΔ51-IFNγ in several subcutaneous and orthotopic tumor models following IT administration. The 4T1 and CT26 tumor models were investigated, as well as NOP23, another breast cancer model that can be implanted orthotopically in the mammary fat pad. The treatment schedules were optimized for each tumor model and are summarized in Supplementary  Figure S4c . Tumors were measured over time and tumor volume was calculated. Figure 6a shows that VSVΔ51-IFNγ was the most efficient at controlling tumor growth in the 4T1 model. Indeed, the differences observed between the PBS and the VSVΔ51-IFNγ-treated group were highly significant within 2 days after initiation of treatment. The reduction in tumor size also translated to a prolongation of survival, with one animal being cured (Figure 6b) . A significant prolongation of survival was also observed for the CT26 and NOP23 tumor models (Figure 6c,d) . To assess whether the improved efficacy observed with VSVΔ51-IFNγ compared to VSVΔ51 was immunemediated, we compared the efficacy of the two viruses in terms of tumor growth and survival of 4T1 tumor-bearing nude mice, which lack T cells. In contrast to the results obtained in immunocompetent mice (Figure 6a,b) , 4T1 tumors in nude mice showed no difference in growth rate or survival following treatment with the two viruses (Figure 6e and Supplementary Figure S4d) . To further support this finding, we repeated the experiment in immunocompetent mice but with depletion of the T-cell compartment (CD3 depletion). As expected, our data show the loss of the survival advantage in absence of T cells (Figure 6f and Supplementary Figure S4e) . Thus, T cells are required for the tumor control mediated by VSVΔ51-IFNγ.
DISCUSSION
In this study, we demonstrate that IFNγ expression by VSVΔ51 induces a more potent antitumor immune response leading to an improved efficacy compared with VSVΔ51 in various murine tumor models. VSVΔ51-IFNγ produces high amounts of functional transgene both in vitro and in vivo. While in vitro only the (Figures 3d and 4a,b) . Although detectable amounts of IFNγ were produced in response to treatment with the parental virus, the improved efficacy observed in various tumor models ( Figures 5 and 6 ) demonstrates the benefits of virus mediated overexpression of IFNγ. These findings suggest that specific production of the cytokine within the tumor microenvironment is beneficial for the antitumor immune response. In addition, the treatment might also be improved by the sustained virus-driven overexpression of IFNγ. We suggest that VSVΔ51-IFNγ, in addition to its direct effects on tumor cells, induces a greater tumor-specific immune response by increasing MHCI antigen presentation by tumor cells (Supplementary Figure S1) as well as enhancing DC maturation (Figure 4a,b) . This antitumor immunity would control tumor growth and even cure some of the animals ( Figure 6 ). Consistent with this theory, we observed a greater antitumor immune response for the mice treated with VSVΔ51-IFNγ compared to the parental virus (Figure 4c ). Although total splenocytes were used for the ELISPOT assay, the cells secreting IFNγ are likely T cells. Indeed, mainly NK cells, macrophages and T cells secrete IFNγ. 4 Of these, only the T cells require antigen stimulation to produce the cytokine. Concurrent with this, NK-cell activation, as measured by CD69 expression at cell surface, was undetectable 96 hours after treatment (Supplementary Figure S3c) . Furthermore, efficacy was completely abrogated when monitoring tumor growth and survival of immunocompromised animal or following T-cell depletion of immunocompetent animals (Figure 6e,f and Supplementary Figure S4d ,e). Given that nude mice are T-cell-deficient and that T-cell depletion also led to this effect, the loss of the phenotype also points to a role of the adaptive arm of immunity for the improved efficacy conferred by the IFNγ-producing virus. The roles of mature DCs and IFNγ in the generation of efficient T-cell responses are well established. Of note, IFNγ was shown to increase proliferation of CD4+ T cells 31 as well as numbers of CD8+ T cells in the context of acute viral infection 32 and we showed increased presence of T cells in the tumors of the VSVΔ51-IFNγ-treated animals (Figure 4d ). Our results show the induction of various proinflammatory factors in vivo in response to treatment with our virus (Figure 3 ). Of these, MCP-1 is known to be induced by IFNγ 33 . While MCP-1 was found to be produced by various cells, macrophages and DCs are the main source. 34 Although we did not observe any difference in the early activation of CD11b+ cells (Figure 4a ), IFNγ is known for its importance in conditioning macrophages for activation 35 and thus, these cells might have important roles to play in different contexts. For instance, the lungs contain a high amount of resident macrophages, which might have an important role to play in this particular setting. On the other hand, we consistently observed a greater activation of DCs following treatment with VSVΔ51-IFNγ (Figure 4a,b and Supplementary Figure S3b) , these cells might contribute to the increased concentration of MCP-1 detected in the serum of the treated animals. Furthermore, MCP-1 is mostly known for its role in attracting monocytic cells; however, it was also shown to attract adoptively-transferred T cells to tumors producing the chemokine. 36 Given the local IT production of IFNγ following treatment with our engineered virus (Figure 3b ), MCP-1 should be locally produced in the tumor and lead to a similar situation. Consistent with this theory, our results show an increase in IT T cells following administration of VSVΔ51-IFNγ compared to the parental virus (Figure 4d ). Other IFNγ-induced factors such as IP-10, which are also known to attract T cells, could be involved in the observed phenotype as well. 37 Despite the fact that IFNγ is well known for its antiviral activity, 38 we did not observe any difference in the amount virus recovered from the tumors 24 hours postinjection (Supplementary Figure  S2a,b) . Although we did not investigate this, expression of the cytokine by the virus may result in inhibition of viral replication at later time points or in normal tissues, thus acting as a safety mechanism. This strategy would be similar to VSV expressing the antiviral cytokine IFNβ, which was shown to have a better safety profile compared with the parental virus. 39 One of the main causes of toxicity following treatment with wild-type VSV is neuro-pathogenesis which results from the replication of the virus in the central nervous system and can lead to paralysis or death. 40 Although type I IFNs are required for the control of VSV infection in peripheral tissues, the lack of induction of these cytokines in the central nervous system seems to be the reason for the virus proliferation observed in the brain. 41 Interestingly, IFNγ was shown to be a key player in the antiviral response to VSV in the central nervous system. 42 Given the established protective role of IFNγ in the brain, one interesting application for VSVΔ51-IFNγ would be for the treatment of glioblastoma and other brain cancers. Further supporting this idea, administration of recombinant IFNγ has been tested in different clinical trials for glioblastoma. Although the results were disappointing, local administration in combination with other therapies was proposed to be a promising avenue. 43 In this study, we demonstrate the improved antitumor efficacy of VSVΔ51-IFNγ compared with VSVΔ51 in various tumor models. These findings further support the notion that engineering OVs to express cytokines can provide additional benefits for cancer immunotherapy.
MATeRIAlS AND MeTHODS

Cell lines and culture
Vero kidney epithelial, 4T1 murine mammary carcinoma, EMT6 murine mammary carcinoma, and CT26 murine colon carcinoma cell lines were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Corning cellgro, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) (Sigma life science, St-Louis, MO) and maintained at 37 °C with 5% CO 2 . NOP23 cells were maintained in high-glucose DMEM supplemented with 10% FBS, 1% insulin transferrin selenium, and 1% pen strep (Fisher Scientific, Waltham, MA).
Viral constructs
The IFNγ gene (1-155) was amplified by PCR on cDNA obtained from RNA extracted from LPS stimulated C57BL/6 murine splenocytes. The forward and reverse primers were designed to include XhoI and NheI restriction sites.
The digested PCR fragment was cloned into the XhoI and NheI digested VSVΔ51 viral backbone, as previously described. 23 
Virus rescue
Rescues were performed as previously described. 44, 45 Briefly, Vero cells were infected with vaccinia virus expressing T7 polymerase at an MOI of 3 for 2 hours. The virus inoculum was then removed and cells were transfected with T7-driven plasmids encoding VSV N, P, and L genes, as well as the VSVΔ51-IFNγ plasmid. Supernatants were collected approximately 48 hours after transfection and passed through a 0.22-μm filter (MillexGP, Carrigtwohill, Ireland) to remove vaccinia virus.
Virus purification
Vero cells were infected at an MOI of 0.01 for 24 hours and culture supernatants were collected and filtered using a 0.2-μm bottle top filter (Millipore, Etobicoke, Canada). The supernatant was then centrifuged at 30,100 g for 1h30 and the pellet was resuspended in Dulbecco's phosphate-buffered saline (Corning cellgro, Manassas, VA). The purified virus was kept at −80 °C.
Titering
Viral titers were obtained by plaque assay. Briefly, serial dilutions of virus were prepared in serum-free DMEM. 100 μl of the dilutions were transferred to monolayers of Vero cells in six-well plates and incubated at 37 °C for 1 hour. After the incubation, cells were overlayed with 0.5% agarose in DMEM supplemented with 10% FBS. Plates were incubated for 24 hours at 37 °C with 5% CO 2 and plaques were counted.
ELISA and ELISPOT
The concentration of IFNγ was obtained using the Quantikine ELISA SixPak, mouse IFNγ (R&D systems, Minneapolis, MN) following the manufacturer's protocol. The IFNγ-secreting cells were assessed using the ELISPOT mouse IFNγ kit (Mabtech, Cincinnati, OH) according to the manufacturer's protocol.
Cell viability assay
The metabolic activity of the cells was assessed using alamarBlue (BIO-RAD, Mississauga, Ontario, Canada) according to the manufacturer's protocol. Briefly, 24 hours postseeding in a 96-well plate (Corning, Manassas, VA), the cells were infected with various amounts of virus. At the indicated time point, 10 μl of alamarBlue was added to each well and the fluorescence was measure at 590 nm upon excitation at 530 nm using a Fluoroskan Ascent FL (Thermo Labsystems, Beverly, MA).
Microscopy
Cells were cultured on coverslips for 24 hours prior to incubation with the conditioned media. Following a 60-minute incubation, the cells were washed with cold PBS and fixed using ice-cold methanol:acetone (1:1). Blocking buffer (5% FBS, 0.3% triton, PBS) and antibody dilution buffer were used (1% bovine serum albumin, 0.3% triton, PBS). The cells were stained using a rabbit anti-STAT1 (Cell signalling technology, Danvers, MA) and a goat antirabbit-594 secondary antibody (Molecular Probes, Waltham, MA). Prolong gold anti-fade with 4' ,6-diamidino-2-phenylindole (Molecular Probes) was used to mount the coverslips onto slides. The images were analyzed using the LSM510 confocal inverted microscope (Zeiss, Oberkochen, Germany).
Western blot
Cells were pelleted and lysed on ice for 30 minutes using 1% NP-40, complete protease inhibitor cocktail (Roche, Mississauga, Ontario, Canada) and phosphatase inhibitor sodium orthovanadate (Calbiochem, Etobicoke, Ontario, Canada) supplemented lysis buffer. Lysates were centrifuged for 5 minutes at 16,000 g and the supernatants were mixed with dithiothreitolsupplemented loading buffer. The samples were migrated on NuPAGE 4-12% Bis-Tris gels (Novex by Life Technology, Carlsbad, CA) and transferred onto PVDF membranes (GE Healthcare, Buckinghanshire, UK) prior to blocking with 50% fetal bovine serum. The membranes were probed for phospho-STAT1, STAT1 and actin (all from Cell Signalling Technology, Danvers, MA). Membranes were then probed with a goat anti-rabbit peroxidase-conjugated antibody (Cederlane, Burlington, Ontario, Canada) and SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) was used to reveal the signal. The gels were analyzed using a FluorChem FC2 (Alpha Innotech, San Leandro, CA).
In vitro IFNγ stimulation
Cells were uninfected or infected with VSVΔ51 or VSVΔ51-IFNγ for 24 hours at an MOI of 3 in serum-free DMEM. Supernatant was collected and filtered using a 0.22-μm filter (MillexGP, Carrigtwohill, IRL) to remove dead cells. To remove the virus from the conditioned media, the cell-cleared supernatant was filtered again by centrifugation at 4,000 g for 45 minutes using Amicon Ultra 50K centrifugal filters (Millipore, Carrigtwohill, IRL). Prior to incubation with the virus-conditioned media, fresh cells were starved for 1h in serumfree DMEM. The cells were then stimulated using the virus-free conditioned media that was preneutralized or not by a 20 minutes incubation with an IFNγ-blocking antibody. Cells were stimulated at 37 °C for 20 minutes and lysed on ice immediately after incubation.
Quantitative PCR
Lungs from treated tumor-bearing mice were homogenized in 500 μl of Dulbecco's phosphate-buffered saline. An aliquot was taken and RNA was extracted using RNeasy RNA extraction kit (QIAGEN, Toronto, Ontario, Canada) according to the manufacturer's protocol. RNA and purity was assessed using a NanoDrop ND-1000 spectrophotometer (Thermoscientific, Waltham, MA) and 500 ng of each sample was used for reverse transcription using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) and Oligo(dT)20 primers (Fisher Scientific). qPCR primers used in this study: VSV N gene forward 5′-GATAGTACCGGAGGATTGACGACTA-3′ and reverse: 5′-TCAAACCATCCGAGCCATTC-3′ and IFNγ gene forward 5′-CTCTT CCTCATGGCTGTTTCT-3′ and reverse 5′-TTCTTCCACATCTATGCCACTT-3′. For the qPCR, SYBR green PCR master mix (Applied Biosystems, Carlsbad, CA) reagent was used according to the manufacturer's protocol and the samples were analyzed using a Rotor-Gene RG3000A (Corbett Research, Mortlake, Australia).
Tumor dissociation
Single cell suspensions were obtained using the mouse tumor cocktail mix, gentle MACS C tubes and gentle MACS dissociator (Miltenyi, San Diego, CA) according to the manufacturer's protocol.
Flow cytometry
Cells were harvested and cell surface staining was performed on ice for 30 minutes. Cells were then washed twice with cold fluorescence-activated cell sorting (FACS) buffer (3% FBS, 0.09% sodium azide, PBS). For surface staining, cells were incubated with combinations of anti-CD122-FITC, -CD69-PE, -CD3-PECY7, -CD11c-APC, and -CD86-FITC (BD Biosciences, San Jose, CA) for 30 minutes. Cells were then washed twice and resuspended in FACS buffer for analysis using a Cyan ADP 9 flow cytometer (Beckman Coulter, Mississauga, Ontario, Canada).
For splenocyte stainings, mice were sacrificed and the spleens were collected at the indicated time points. The spleens were mashed through 70 μm cell strainers (Fisher, Waltham, MA) in FACS buffer (3% serum, 0.09% sodium azide, PBS). Lysis of red blood cells was performed using ACK lysis buffer (0.15M sodium chloride, 10 mmol/l potassium bicarbonate, 0.1 mmol/l disodium ethylenediaminetetraacetic acid, pH7.2). Upon resuspension in FACS buffer, the splenocytes were counted and 1 million cells per condition were stained following the same procedure describes above.
Blood collection and cytometric bead array Blood samples were collected using lithium-heparin-coated capillary tubes (Sarstedt, Newton, NC). Samples were kept at room temperature and centrifugated at 16,000 g for 5 minutes to collect the serum. To determine the concentration of IFNγ, TNFα, MCP-1, and IL-6, cytometric bead array (BD Biosciences) was used according to the manufacturer's protocol.
In vivo experiments and tumor models
All experiments were performed in accordance with institutional guidelines for animal care (University of Ottawa). For the mouse tumor models, Balb/c and nude mice (Charles River Laboratories, Wilmington, MA) were used. For the 4T1 tumor models, 2 × 10 5 cells were injected in the second right fatpad (orthotopic model) or 1 × 10 5 cell were injected intravenously (lung tumor model). For the CT26 tumor model, 4 × 10 5 cells were injected subcutaneously in the right flank. For the NOP23 model, 1 × 10 6 cells were injected into the mammary fat pad of MMTV/neu OT-I/OT-II mice which are bred on the C57BL/6 background. 46 For intravenous and IT injections, the virus preparations were diluted to the appropriate concentration in a total volume of 100 μl of PBS and injected IT or intravenously using insulin syringes (The Stevens Co, Montreal, Québec, Canada).
For T-cell depletion, anti-CD3e antibody (BioXcell, West Lebanon, NH) was injected IP 24 hours prior to the beginning of virus treatment.
Tumor measurements
The length and width of the tumors were measured using digital calipers (Fowler, Newton, MA) and the tumor volume was calculated using the following formula (width 2 *length)/2. The mice were considered end-point when they showed respiratory distress, displayed significant weight lost or when the tumor volume reached 1,500 mm M-C Bourgeois-Daigneault et al.
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Official journal of the American Society of Gene & Cell Therapy 48 hours. The tissues were embedded in paraffin and sections were stained using hematoxylin and eosin. The tumor diameters were measured from sections scanned with the Aperio ScanScope using ImageScope software.
India ink lung perfusion
After euthanization, the ribcage was opened and the trachea was exposed. India ink solution (50% india ink (Super black Statesville, NC), 50% PBS (Corning cellgro)) was injected directly into the trachea using a 23 gauge needle (BD Biosciences). Immediately after perfusion, the lungs were removed and fixed by immersion into Feketeye solution (70% ethanol, 10% formaldehyde, 5% glacial acetic acid) to reveal the tumors.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0 software. Statistical significance was calculated using Student's T-test with Welch's correction, one-way or two-way analysis of variance or Mann-Whitney U-test as indicated in the figure legends. Error bars represent standard error of the mean.
